From Rescue to Interception: The PREVENT 2-LATE (PReserve Eligibility Via Early, Necessary Transfer) Framework for Advanced Heart Failure
Journal of Cardiac Failure · 2026-10 · 32 (10) · 1781-1794
DOI: 10.1016/j.cardfail.2026.07.010 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cardiac Failure, 2026-10. Verfasst von Mandeep R Mehra und 13 weiteren Autor:innen. Beteiligte Einrichtung: Mass General Brigham Heart and Vascular Institute and Harvard Medical School, Boston, Massachusetts. Electronic address: mmehra@bwh.harvard.edu. Hauptthemen laut MEDLINE: Heart Failure, Heart-Assist Devices, Heart Transplantation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
The management of advanced heart failure has been transformed by 2 parallel developments that have not yet been fully translated into clinical practice. Heart transplantation and durable left ventricular assist device (LVAD) support confer contemporary 1-year survival approaching 90%; yet, these therapies frequently are deployed only after the onset of progressive right ventricular dysfunction, cardiorenal injury, severe frailty, and hemodynamic instability, which are conditions that elevate procedural risk, impair long-term outcomes, and may ultimately preclude candidacy for advanced therapies altogether. The central limitation in advanced heart failure is therefore no longer the absence of effective therapies but the failure to identify and refer patients during the therapeutic window when physiologic reserve remains intact. This special communication advances 2 related but distinct objectives. First, we propose PREVENT 2-LATE (PReserve Eligibility Via Early, Necessary Transfer), a pragmatic referral framework in which the presence of any 2 of 4 early signals including escalating Loop diuretic requirements, recurrent Admissions, Therapy intolerance, and Early electrical, echocardiographic, or end-organ deterioration supplemented by persistently elevated natriuretic peptides-should prompt consideration for referral through shared care to an advanced heart failure program. These LATE criteria are designed to identify patients earlier in the disease trajectory than existing frameworks, when the full breadth of advanced therapy options is still intact. We further propose a multidisciplinary in-reach model, embedding advanced heart failure expertise within high-risk cardiovascular programs, including electrophysiology, structural heart, cardiogenic shock, cardiac surgery, and specialized cardiomyopathy services, to proactively identify and intercept residual risk before conventional referral triggers emerge. Second, and equally important, this communication provides a consolidated framework for contemporary LVAD best practices, an area in which clinical evidence has advanced rapidly but awareness and adoption remain inconsistent. We synthesize current evidence on morbidity decompression, pharmacologic optimization including renin-angiotensin-aldosterone system inhibition, myocardial recovery, frailty reversibility, and therapeutic sequencing including LVAD-first strategies, with the explicit goal of equipping clinicians to deploy these therapies earlier and more confidently. Critically, PREVENT 2-LATE is not designed to increase use of any single modality. Both heart transplantation and LVAD support are effective, and the framework exists precisely to preserve optionality across the full spectrum of advanced heart failure therapies, enabling expert multidisciplinary teams to match the right intervention to the right patient at the right time. The future of advanced heart failure lies not in increasingly urgent rescue after irreversible decline but in systematic interception while options remain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Mass General Brigham Heart and Vascular Institute and Harvard Medical School, Boston, Massachusetts. Electronic address: mmehra@bwh.harvard.edu.
- Center for Advanced Heart and Lung Disease, Baylor University Medical Center, The Heart Hospital, Dallas, Texas.
- Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.
- Division of Cardiovascular Medicine, University of Chicago Department of Medicine, Chicago, Illinois.
- The Second Department of Internal Medicine, University of Toyama, Toyama, Japan.
- Cardiac Surgery Clinic, University Clinical Center of Serbia, Belgrade, Serbia.
Zitieren
APA
Mehra, M. R., Nayak, A., Savarese, G., Kanwar, M. K., Hall, S., Kinugawa, K., Vukicevic, M., Cikes, M., Desai, A. S., Molina, E. J., Givertz, M. M., Crespo-Leiro, M. G., Goldstein, D. J., & Kormos, R. L. (2026). From Rescue to Interception: The PREVENT 2-LATE (PReserve Eligibility Via Early, Necessary Transfer) Framework for Advanced Heart Failure. Journal of Cardiac Failure, 32(10), 1781-1794. https://doi.org/10.1016/j.cardfail.2026.07.010
Vancouver
Mehra MR, Nayak A, Savarese G, Kanwar MK, Hall S, Kinugawa K, et al. From Rescue to Interception: The PREVENT 2-LATE (PReserve Eligibility Via Early, Necessary Transfer) Framework for Advanced Heart Failure. Journal of Cardiac Failure. 2026;32(10):1781-1794. doi:10.1016/j.cardfail.2026.07.010
BibTeX
@article{Mehra2026,
author = {Mehra, Mandeep R and Nayak, Aditi and Savarese, Gianluigi and Kanwar, Manreet K and Hall, Shelley and Kinugawa, Koichiro and Vukicevic, Milica and Cikes, Maja and Desai, Akshay S and Molina, Ezequiel J and Givertz, Michael M and Crespo-Leiro, Maria G and Goldstein, Daniel J and Kormos, Robert L},
title = {From Rescue to Interception: The PREVENT 2-LATE (PReserve Eligibility Via Early, Necessary Transfer) Framework for Advanced Heart Failure},
journal = {Journal of Cardiac Failure},
year = {2026},
volume = {32},
number = {10},
pages = {1781--1794},
doi = {10.1016/j.cardfail.2026.07.010}
}
EUVIMED